A phase II trial of ProscaVax in advanced late-stage prostate cancer patients

Trial Profile

A phase II trial of ProscaVax in advanced late-stage prostate cancer patients

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs PSA-IL2-GM-CSF vaccine (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Mar 2018 According to an OncBioMune Pharmaceuticals media release, the company has selected Theradex as its contract research organization (CRO) for this and other planned phase 2 clinical trial (261722).
    • 28 Feb 2018 According to an OncBioMune media release, full protocol for this trial has been submitted to Urology Centers of North Texas (UCNT) for review. Upon review by UCNT, OncBioMune management will make any requisite adjustments and submit the protocol to the U.S. Food and Drug Administration.
    • 26 Feb 2018 According to an OncBioMune media release, the company is preparing the protocol for this trial for FDA submission. For FDA approval the company will use a central IRB (Institutional Review Board), as central IRBs move much faster than most university IRBs.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top